Peptides DB
Research-centric peptide and protocol reference hub
Study 32 of 32LL-37 literaturebiorxiv-preprint · Observational2026

Valorisation of invasive North Sea macroalgae as functional feed additives to improve disease resilience in Pacific white shrimp (Litopenaeus vannamei)

Invasive North Sea macroalgae may enhance disease resilience in Pacific white shrimp, but no growth benefits were observed in this study.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the ll-37 corpus
6
Preclinical
17
Observational · this one
0
Open-label
5
Randomised
4
Reviews

Summary and findings

This study evaluated the use of invasive North Sea macroalgae as feed additives to enhance disease resilience in Pacific white shrimp (Litopenaeus vannamei) challenged with Vibrio parahaemolyticus. Shrimp were fed diets containing 1% or 3% seaweed extract for 28 days. The study found improved survival rates in shrimp fed the seaweed-supplemented diets compared to controls.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Survival increased from 60.00 ± 12.02% in the control to 74.44 ± 8.39% in the seaweed-supplemented group.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Ulva australisSargassum muticumSeaweed phytochemicalsAquaculture nutritionLitopenaeus vannameiAHPNDGut microbiomeGrowth performanceInvasive macroalgae such as Ulva australis and Sargassum muticum are increasingly abundant along European coastlines and represent a potentially valuable source of bioactive compounds for sustainable aquaculture. This study evaluated the potential of invasive North Sea macroalgae as functional feed additives to enhance disease resilience in Pacific white shrimp (Litopenaeus vannamei) challenged with Vibrio parahaemolyticus. Extracts from two U. australis populations (The Netherlands and France) and one S. muticum population were prepared using 70% ethanol and characterized through proximate composition analysis, total phenolic content (TPC), and HPLC. Antibacterial activity against V. parahaemolyticus was assessed using minimum inhibitory concentration (MIC) assays. Shrimp post-larvae (PL10; 42 ± 0.6 mg) were fed diets containing 1% or 3% seaweed extract for 28 days, after which growth performance, survival, resistance to V. parahaemolyticus, and gut microbiome composition were evaluated.Gallic acid and quercetin were detected in all seaweed extracts. Total phenolic content was highest in U. australis from the Netherlands (269 ± 7.86 µg GAE g⁻¹), followed by S. muticum (89 ± 8.65 µg GAE g⁻¹) and U. australis from France (69 ± 6.50 µg GAE g⁻¹). Antibacterial activity was likewise observed for all seaweed extracts, with MIC values of 12.5 mg mL⁻¹ for U. australis and 25 mg mL⁻¹ for S. muticum. Shrimp fed seaweed-supplemented diets exhibited significantly higher survival rates following the V. parahaemolyticus challenge compared to the control group (p < 0.05). The strongest protective effect was observed in the 3% U. australis (The Netherlands) treatment group, where survival increased from 60.00 ± 12.02% in the control to 74.44 ± 8.39% in the seaweed-supplemented group. In contrast, weight gain, specific growth rate, and feed conversion ratio were generally superior in the control group. Gut microbiome composition showed treatment-related shifts in bacterial abundance, although overall microbial diversity remained unchanged.These results indicate that invasive North Sea macroalgae can be valorised as functional aquafeed ingredients that enhance resistance against V. parahaemolyticus infection in L. vannamei. Although growth benefits were not observed, the improved post-challenge survival highlights the potential of these seaweed extracts as functional feed additives contributing to more resilient and sustainable shrimp aquaculture.</p>

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the LL-37 corpus

BAn audit assessing data quality, viral suppression, and transition to dolutegravir among children and adolescents with HIV in care at eThekwini Municipality, South Africabiorxiv-preprint · 2026 · 10% had a last VL ≥1000 copies/mL.HumanDCoarse composition suffices: tabular in-context learning for multi-activity antimicrobial peptide profilingbiorxiv-preprint · 2026 · mAP-5=77.8% on ESCAPE benchmark, n=82,359 peptides.reviewBHuman cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity.Current eye research · 2005 · EC50 values for three strains of Pseudomonas aeruginosa were 2.8 +/- 1.3, 1.9 +/- 0.3, and 3.6 +/- 2.1 microg/ml.HumanCPhenotypic resistance to life-saving antimicrobials in Gram-positive bacteria isolated from wild birds in Northern Italy: a One Health surveillance perspective.One health (Amsterdam, Netherlands) · 2026 · n=205 · 40.1% of isolates were Gram-positive, n=469.AnimalAAzithromycin for Preschoolers with Wheezing in the Emergency Department.The New England journal of medicine · 2026 · ADYC scores did not differ significantly between the azithromycin and placebo groups in the positive cohort (P = 0.70).HumanACarbocisteine or Hypertonic Saline for Acute Respiratory Failure.The New England journal of medicine · 2026 · Median duration of mechanical ventilation was 186.1 hours with carbocisteine and 172.7 hours with no carbocisteine, adjusted hazard ratio 0.96, P=0.34.Human